For the quarter ending 2026-03-31, LYEL had $30,590K increase in cash & cash equivalents over the period. -$38,599K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -24,153 | -140,723 | -38,846 | -94,879 |
| Acquired ipr&d expense | - | 66,332 | - | - |
| Stock-based compensation expense | 4,295 | 25,569 | 5,232 | 11,028 |
| Loss on securities purchase agreement put/call | - | -15,156 | -4,029 | - |
| Depreciation and amortization expense | 2,332 | 2,397 | 2,566 | 6,576 |
| Non-cash lease income | 1,100 | 1,039 | 995 | 1,516 |
| Impairment of other investments | - | 0 | 0 | 0 |
| Impairment of long-lived assets | - | 0 | 0 | 1,443 |
| Net amortization and accretion on marketable securities | 886 | 1,060 | 1,009 | 2,890 |
| Change in fair value of success payment liabilities | -353 | 610 | 461 | -240 |
| Gain on securities purchase agreement put/call | 17,561 | - | - | - |
| Loss on property and equipment disposals, net | 0 | 166 | 249 | -3,759 |
| Change in fair value of contingent consideration payable | 0 | 0 | -369 | 2,075 |
| Loss on marketable equity security | 0 | -1 | -1 | -28 |
| Prepaid expenses, other current assets and other assets | -90 | 2,393 | -420 | -4,796 |
| Accounts payable | 2,383 | 325 | -779 | -1,885 |
| Accrued liabilities and other current liabilities | -3,567 | 4,904 | 572 | -13,118 |
| Other non-current liabilities | 10 | -2,164 | -349 | -223 |
| Net cash used in operating activities | -38,510 | -32,251 | -28,577 | -89,196 |
| Purchases of property and equipment | 89 | 304 | 62 | 414 |
| Sales of property and equipment | - | 24 | 263 | - |
| Purchases of marketable securities | 37,183 | 42,800 | 70,987 | 165,112 |
| Maturities of marketable securities | 54,650 | 52,910 | 74,135 | 247,639 |
| Acquisition of assets, net of cash acquired | - | 41,195 | - | - |
| Net cash provided by investing activities | 17,378 | -31,365 | 3,349 | 82,113 |
| Proceeds from equity issuance/offering-Securities Purchase Agreement | 50,000 | - | - | - |
| Proceeds from employee stock purchase plan | - | 181 | 0 | 184 |
| Proceeds from securities purchase agreement equity issuance | - | 0 | 50,000 | - |
| Proceeds from equity issuance/offering-At The Market Offering | 1,696 | - | - | - |
| Proceeds from exercise of stock options | 26 | 42 | 0 | 0 |
| Taxes paid related to net share settlement of equity awards | 0 | 1 | 0 | 0 |
| Net cash provided by financing activities | 51,722 | 222 | 50,000 | 184 |
| Net increase in cash, cash equivalents and restricted cash | 30,590 | -63,394 | 24,772 | -6,899 |
| Cash, cash equivalents and restricted cash at beginning of period | 61,766 | 125,160 | 107,287 | - |
| Cash, cash equivalents and restricted cash at end of period | 92,356 | 61,766 | 125,160 | - |
Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL)